Company Overview of aTyr Pharma Inc.
Key Executives for aTyr Pharma Inc.
|John D. Mendlein Ph.D., J.D.||81 Relationships||Chief Executive Officer and Director||56|
|Paul R. Schimmel Ph.D.||90 Relationships||Founder, Director and Member of Compensation Committee||75|
|Xiang-Lei Yang Ph.D.||No Relationships||Founder||--|
|John T. Blake CPA||No Relationships||Vice President of Finance||40|
|David J. King Ph.D.||No Relationships||Senior Vice President of Research||--|
|View More Key Executives|
aTyr Pharma Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|John K. Clarke||75 Relationships||Alnylam Pharmaceuticals, Inc.||62|
|John D. Mendlein Ph.D., J.D.||81 Relationships||aTyr Pharma Inc.||56|
|Paul R. Schimmel Ph.D.||90 Relationships||aTyr Pharma Inc.||75|
|James C. Blair Ph.D.||164 Relationships||Domain Associates, L.L.C.||76|
|Kathryn E. Falberg||54 Relationships||The Trade Desk, Inc.||55|
aTyr Pharma Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee||Kathryn E. Falberg||54 Relationships||2 Executives|
|Compensation Committee Ph.D.||James C. Blair||164 Relationships||3 Executives|
|Nominating Committee||John K. Clarke||75 Relationships||2 Executives|
|Corporate Governance Committee||John K. Clarke||75 Relationships||2 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation||$472.8K|
|Total Value of Options|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.